Relationship between myocardial beta-adrenergic sensitivity and heart rate variability

Annals of Noninvasive Electrocardiology

Volumn 5, Issue 2, 2000, Pages 111-118

  Cabrol, Philippe ^a   Galinier, Michel ^a   Pathak, Atul ^a   Fourcade, Joëlle ^a   Soûla, Philippe ^a   Tran, Marie Antoinette ^a   Boveda, Serge ^a   Montastruc, Jean Louis ^a   Fauvel, Jean Marie ^a   Senard, Jean Michel ^a  

^a CHU RANGUEIL   (France)

Author keywords

Heart rate variability; Myocardial beta adrenergic sensitivity

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CATECHOLAMINE; DOBUTAMINE; ISOPRENALINE; NORADRENALIN;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HEART MUSCLE; HEART RATE VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOLTER MONITORING; HUMAN; MALE; PARASYMPATHETIC NERVE; PATHOGENESIS; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RECEPTOR BINDING; VALVULAR HEART DISEASE;

EID: 0034043617     PISSN: 1082720X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2000.tb00375.x     Document Type: Article

References (40)

1. Akselrod R, Gordon D, Übel F, et al. Power spectrum analysis of heart rate fluctuations: a quantitative probe of beat-to-beat cardiovascular control. Science 1981;59:179193.
2. Pomeranz B, MacAulay R, Caudill M, et al. Assessment of aotonomic function in humans by heart rate analysis. Am J Physiol 1985;248:H151-H153.
3. Task Force of the European Society and the North American Society of Pacing and Electrophysiology. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Circulation 1996;93:1043-1065.
4. Kleiger R, Miller P, Bigger J, et al. and The Multicenter Post Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-262.
5. Saul J, Arai Y, Berger R, et al. Assessment of autonomie regulation in chronic congestive heart failure by heart rate spectral analysis. Am J Cardiol 1988;62:1292-1299.
6. Kienzle M, Ferguson D, Birkett C, et al. Clinical, hemodynamic and sympathetic neural correlates of heart rate variability in congestive heart failure. Am J Cardiol 1992;69: 761-767.
7. Coumel P, Hermida JS, Wennerblöm B, et al. Heart rate variability in left ventricular hypertrophy and heart failure and the effects of beta-blockade. A nonspectral analysis of heart rate variability. Eur Heart J 1991;12:412-422.
8. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure. Results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-Heart). Circulation 1998; 98:1510-1516.
9. Ponikowski P, Anker SD, Chua TP, et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischémie or idiopathic dilated cardiomyopathy. Am J Cardiol 1997;79: 1645-1650.
10. Fauchier L, Babuty D, Cosnay P, et al. Heart rate variability in idiopathic dilated cardiomyopathy: Characteristics and prognostic value. J Am Coll Cardiol 1997;30:1009-1014.
11. Leimbach WN, Wallin BG, Victor RG, et al. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;5:913-919.
12. Esler M, Kaye D, Lambert G, et al. Adrenergic nervous system in heart failure. Am J Cardiol 1997;80(11A):7L-14L.
13. Van de Borne P, Montano N, Pagani M, et al. Absence of low-frequency variability of sympathetic nerve activity in severe heart failure. Circulation 1997;95:1449-1454.
14. Kingwell BA, Thompson JM, Kaye D, et al. Heart rate spectral analysis, cardiac norepinephrine spillover, and muscle sympathetic activity during human sympathetic nervous activation and failure. Circulation 1994;90:234240.
15. Hasking GJ, Esler MD, Jennings GJ, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-621.
16. Meredith IT, Eisenhofer G, Lambert GW, et al. Cardiac sympathetic activity in congestive heart failure: Evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 1993;88:136-145.
17. Kaye DM, Lambert GW, Lefkovits J, et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 1994;23:570578.
18. Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996;93:1667-1676.
19. Casolo GC, Stroder P, Sulla A, et al. Heart rate variability and functional severity of congestive heart failure secondary to coronary artery disease. Eur Heart J 1995; 16:360367.
20. Pagani M, Lombard! F, Guzzetti S, et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res 1986;59:178-193.
21. Mansier P, Medigue C, Charlotte N, et al. Decreased heart rate variability in transgenic mice overexpressing atrial ladrenoceptors. Am J Physiol 1996;271:H1465-1472.
22. Akselrod R. Spectral analysis of fluctuations in cardiovascular parameters: a quantitative tool for the investigation of autonomie control. Trends Pharmacol Sei 1988;9:6-9.
23. Tuttle R, Mills J. Dobutamine: Development of a new catecholamine to selectively increase cardiac contractility. Circ Res 1975;36:185-188.
24. Leier C, Webel J, Bush C. The cardiovascular effects of dobutamine in patients with severe cardiac failure. Circulation 1977;56:468-472.
25. McPherson GA. Analysis of radioligand binding experiments: A collection of computer programs for the IBM PC. J Pharmacol Meth 1985;14:231-238.
26. Parati G, Di Rienzo M, Bertinieri G, et al. Evaluation of the baroreceptor-heart reflex by 24-hour intra-arterial blood pressure monitoring in humans. Hypertension 1988; 12:214-222.
27. Ahmed MW, Kadish AL, Parker MA, et al. Effect of physiologic and pharmacologie adrenergic stimulation on heart rate variability. J Am Coll Cardiol 1994;24:1082-1090.
28. Brodde OE, Michel MC, Zerkowski HR. Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. Cardiovasc Res 1995;30: 570-584.
29. Bristow MR, Glinsberg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med 1982;307:205211.
30. Bristow M, Hershberger R, Port J, et al. -adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990;82 (Suppl. I):I12-I25.
31. Brodde OE. Adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991;43:203-242.
32. Grasso R, Schena F, Gulli G, et al. Does low-frequency variability of heart period reflect a specific parasympathetic mechanism? J Auton Nerv Syst 1996;63:30-38.
33. Malik M, Camm J. Components of heart rate variability. What they really mean and what we really measure. Am J Cardiol 1993;72:821-822.
34. DeBoer RW, Karemaker JM, Strackee J. Hemodynamic fluctuations and baroreflex sensitivity in humans. Am J Physiol 1987;253:H680-689.
35. Mandawat M, Wallbridge DR, Pringle SD, et al. Heart rate variability in left ventricular hypertrophy. Br Heart] 1995; 73:139-144.
36. Lombard! F, Torzillo D, Sandrone G, et al. Autonomie effects of antiarrhythmic drugs and their importance. Eur HeartJ 1992;13(Suppl. F):F38-43.
37. Bonaduce D, Marciano F, Pettreta M, et al. Effects of converting enzyme inhibition on heart period variability in patients with acute myocardial infarction. Circulation 1994; 90:108-113.
38. Binkley PF, Haas GJ, Starling RC, et al. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol 1993;21:655-661.
39. Krum H, Bigger JT, Goldsmith RL, et al. Effect of long-term digoxin therapy on autonomie function in patients with chronic heart failure. J Am Coll Cardiol 1995;25:289-294.
40. Swynghedauw B, Jasson S, Chevalier B, et al. Heart rate and heart rate variability, a pharmacological target. Cardiovasc Drugs Ther 1996; 10:677-685.